157 related articles for article (PubMed ID: 27895768)
1. Role of miR-196 and its target gene HoxB8 in the development and proliferation of human colorectal cancer and the impact of neoadjuvant chemotherapy with FOLFOX4 on their expression.
Shen S; Pan J; Lu X; Chi P
Oncol Lett; 2016 Nov; 12(5):4041-4047. PubMed ID: 27895768
[TBL] [Abstract][Full Text] [Related]
2. Identification of HOXB8 and KLK11 expression levels as potential biomarkers to predict the effects of FOLFOX4 chemotherapy.
Li S; Lu X; Chi P; Pan J
Future Oncol; 2013 May; 9(5):727-36. PubMed ID: 23647300
[TBL] [Abstract][Full Text] [Related]
3. Folfox4 regimen administered through combined hepatic arterial and systemic infusion for treatment of colorectal cancer with unresectable liver metastases.
Guan M; Chen SC; Ying HY; Zhao L; Li XY; Zhou JF; Shao YJ; Yang XD; Lin Y; Ning XH; Bai CM
Chin Med J (Engl); 2012 Oct; 125(20):3640-5. PubMed ID: 23075717
[TBL] [Abstract][Full Text] [Related]
4. Randomized multicenter phase II trial of bolus plus infusional fluorouracil/leucovorin compared with fluorouracil/leucovorin plus oxaliplatin as third-line treatment of patients with advanced colorectal cancer.
Kemeny N; Garay CA; Gurtler J; Hochster H; Kennedy P; Benson A; Brandt DS; Polikoff J; Wertheim M; Shumaker G; Hallman D; Burger B; Gupta S
J Clin Oncol; 2004 Dec; 22(23):4753-61. PubMed ID: 15570076
[TBL] [Abstract][Full Text] [Related]
5. [Analysis on safety and preliminary efficacy of dose-modified regimen of 5-fluorouracil plus oxaliplatin and irinotecan (FOLFOXIRI) in advanced colorectal cancer].
Cai Y; Deng R; Hu H; Zhang J; Ling J; Wu Z; Yang L; Li J; Deng Y
Zhonghua Wei Chang Wai Ke Za Zhi; 2018 Sep; 21(9):1045-1050. PubMed ID: 30269326
[TBL] [Abstract][Full Text] [Related]
6. Multicenter phase II study of bimonthly high-dose leucovorin, fluorouracil infusion, and oxaliplatin for metastatic colorectal cancer resistant to the same leucovorin and fluorouracil regimen.
André T; Bensmaine MA; Louvet C; François E; Lucas V; Desseigne F; Beerblock K; Bouché O; Carola E; Merrouche Y; Morvan F; Dupont-André G; de Gramont A
J Clin Oncol; 1999 Nov; 17(11):3560-8. PubMed ID: 10550155
[TBL] [Abstract][Full Text] [Related]
7. [A clinical study of paclitaxel combined with FOLFOX4 regimen as neoadjuvant chemotherapy for advanced gastric cancer].
Qu JJ; Shi YR; Liu FR; Ma SQ; Ma FY
Zhonghua Wei Chang Wai Ke Za Zhi; 2010 Sep; 13(9):664-7. PubMed ID: 20878572
[TBL] [Abstract][Full Text] [Related]
8. [FOLFOX4 regimen versus DP(O)F regimen for advanced gastric cancer].
Wu F; Zhang HG; Ran FW; Zhang XR; Shi YK
Ai Zheng; 2008 Apr; 27(4):413-7. PubMed ID: 18423129
[TBL] [Abstract][Full Text] [Related]
9. Randomized controlled trial of reduced-dose bolus fluorouracil plus leucovorin and irinotecan or infused fluorouracil plus leucovorin and oxaliplatin in patients with previously untreated metastatic colorectal cancer: a North American Intergroup Trial.
Goldberg RM; Sargent DJ; Morton RF; Fuchs CS; Ramanathan RK; Williamson SK; Findlay BP; Pitot HC; Alberts S
J Clin Oncol; 2006 Jul; 24(21):3347-53. PubMed ID: 16849748
[TBL] [Abstract][Full Text] [Related]
10. MiR-32-5p regulates the proliferation and metastasis of cervical cancer cells by targeting HOXB8.
Liu YJ; Zhou HG; Chen LH; Qu DC; Wang CJ; Xia ZY; Zheng JH
Eur Rev Med Pharmacol Sci; 2019 Jan; 23(1):87-95. PubMed ID: 30657550
[TBL] [Abstract][Full Text] [Related]
11. A Phase II Study of Modified FOLFOX4 for Colorectal Cancer Patients with Peritoneal Carcinomatosis.
Lee DH; Oh SY; Lee YR; Huh SJ; Yoon HH; Kim SH; Lee S; Lee JH; Kim Y; Kim HJ; Kwon HC
Cancer Res Treat; 2011 Dec; 43(4):225-30. PubMed ID: 22247707
[TBL] [Abstract][Full Text] [Related]
12. Superiority of oxaliplatin and fluorouracil-leucovorin compared with either therapy alone in patients with progressive colorectal cancer after irinotecan and fluorouracil-leucovorin: interim results of a phase III trial.
Rothenberg ML; Oza AM; Bigelow RH; Berlin JD; Marshall JL; Ramanathan RK; Hart LL; Gupta S; Garay CA; Burger BG; Le Bail N; Haller DG
J Clin Oncol; 2003 Jun; 21(11):2059-69. PubMed ID: 12775730
[TBL] [Abstract][Full Text] [Related]
13. Oxaliplatin, fluorouracil, and leucovorin versus fluorouracil and leucovorin as adjuvant chemotherapy for locally advanced rectal cancer after preoperative chemoradiotherapy (ADORE): an open-label, multicentre, phase 2, randomised controlled trial.
Hong YS; Nam BH; Kim KP; Kim JE; Park SJ; Park YS; Park JO; Kim SY; Kim TY; Kim JH; Ahn JB; Lim SB; Yu CS; Kim JC; Yun SH; Kim JH; Park JH; Park HC; Jung KH; Kim TW
Lancet Oncol; 2014 Oct; 15(11):1245-53. PubMed ID: 25201358
[TBL] [Abstract][Full Text] [Related]
14. Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study.
Douillard JY; Siena S; Cassidy J; Tabernero J; Burkes R; Barugel M; Humblet Y; Bodoky G; Cunningham D; Jassem J; Rivera F; Kocákova I; Ruff P; Błasińska-Morawiec M; Šmakal M; Canon JL; Rother M; Oliner KS; Wolf M; Gansert J
J Clin Oncol; 2010 Nov; 28(31):4697-705. PubMed ID: 20921465
[TBL] [Abstract][Full Text] [Related]
15. Clinical Significance of MMP7 Levels in Colorectal Cancer Patients Receiving FOLFOX4 Chemotherapy Treatment.
Zhou Y; Wang L; Zhou F
Int J Gen Med; 2023; 16():2671-2678. PubMed ID: 37398512
[TBL] [Abstract][Full Text] [Related]
16. Oxaliplatin, fluorouracil, and leucovorin with or without cetuximab in patients with resected stage III colon cancer (PETACC-8): an open-label, randomised phase 3 trial.
Taieb J; Tabernero J; Mini E; Subtil F; Folprecht G; Van Laethem JL; Thaler J; Bridgewater J; Petersen LN; Blons H; Collette L; Van Cutsem E; Rougier P; Salazar R; Bedenne L; Emile JF; Laurent-Puig P; Lepage C;
Lancet Oncol; 2014 Jul; 15(8):862-73. PubMed ID: 24928083
[TBL] [Abstract][Full Text] [Related]
17. Prognostic and clinic-pathological significances of HOXB8, ILK and FAT4 expression in colorectal cancer.
Abuderman AA; Harb OA; Gertallah LM
Contemp Oncol (Pozn); 2020; 24(3):183-192. PubMed ID: 33235545
[TBL] [Abstract][Full Text] [Related]
18. Upfront FOLFOXIRI plus bevacizumab and reintroduction after progression versus mFOLFOX6 plus bevacizumab followed by FOLFIRI plus bevacizumab in the treatment of patients with metastatic colorectal cancer (TRIBE2): a multicentre, open-label, phase 3, randomised, controlled trial.
Cremolini C; Antoniotti C; Rossini D; Lonardi S; Loupakis F; Pietrantonio F; Bordonaro R; Latiano TP; Tamburini E; Santini D; Passardi A; Marmorino F; Grande R; Aprile G; Zaniboni A; Murgioni S; Granetto C; Buonadonna A; Moretto R; Corallo S; Cordio S; Antonuzzo L; Tomasello G; Masi G; Ronzoni M; Di Donato S; Carlomagno C; Clavarezza M; Ritorto G; Mambrini A; Roselli M; Cupini S; Mammoliti S; Fenocchio E; Corgna E; Zagonel V; Fontanini G; Ugolini C; Boni L; Falcone A;
Lancet Oncol; 2020 Apr; 21(4):497-507. PubMed ID: 32164906
[TBL] [Abstract][Full Text] [Related]
19. Oxaliplatin based chemotherapy and concomitant highly active antiretroviral therapy in the treatment of 24 patients with colorectal cancer and HIV infection.
Berretta M; Lleshi A; Cappellani A; Bearz A; Spina M; Talamini R; Cacopardo B; Nunnari G; Montesarchio V; Izzi I; Lanzafame M; Nasti G; Basile F; Berretta S; Fisichella R; Schiantarelli C C; Garlassi E; Ridolfo A; Guella L; Tirelli U
Curr HIV Res; 2010 Apr; 8(3):218-22. PubMed ID: 20158458
[TBL] [Abstract][Full Text] [Related]
20. [Comparative study on treatment of advanced colorectal cancer by Aidi injection combined with FOLFOX4 regimen and by FOLFOX4 regimen alone].
Li HJ; Dong L; Fu SY
Zhongguo Zhong Xi Yi Jie He Za Zhi; 2007 Dec; 27(12):1086-9. PubMed ID: 18198641
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
